• Median Technologies posted a net loss of EUR 34.07 million, with basic and diluted loss per share narrowing to EUR 0.93.
• Revenue rose to EUR 23.36 million, while operating loss narrowed to EUR 16.27 million.
• Net financial result worsened to a loss of EUR 17.66 million, including other financial charges of EUR 14.48 million.
• Cash and cash equivalents climbed to EUR 18.25 million, while non-current financial liabilities increased to EUR 22.98 million.
• Median won FDA 510(k) clearance for eyonis LCS, started US commercialization, and expects first US sites to be operational in the third quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Median Technologies SA published the original content used to generate this news brief on May 21, 2026, and is solely responsible for the information contained therein.